U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07053800) titled 'Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis' on May 13.
Brief Summary: This trial aims to find out if obe-cel gets rid of harmful B cells that contribute to systemic lupus erythematosus (SLE)/lupus nephritis (LN) when available treatments have not worked (refractory).
The objective is to look for benefits of obe-cel in making signs of LN completely disappear (remission) at 6 months after treatment in patients with severe, active LN. We will also look for other benefits of obe-cel for up to 24 months after treatment, including the percentage of patients who respond to obe-cel treatment, SLE/...